share_log

Form 144 | Ligand Pharmaceuticals(LGND.US)高管拟出售5,156股股份,价值约44.68万美元

Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 446.84K in Common Stocks

Futu News ·  May 18 05:49

SEC FILLINGS DISCLOSED/ May 17, $Ligand Pharmaceuticals (LGND.US)$$LIGAND PHARMACEUTICAL INC (LGNDZ.US)$$LIGAND PHARMACEUTICAL INC (LGNXZ.US)$$LIGAND PHARMACEUTICAL INC (LGNYZ.US)$$LIGAND PHARMACEUTICAL INC (LGNZZ.US)$ Officer Espinoza Octavio intends to sell 5,156 shares of its common stock on May 17, with a total market value of approximately $446.84K.

Espinoza Octavio has reduced shareholding in $Ligand Pharmaceuticals (LGND.US)$$LIGAND PHARMACEUTICAL INC (LGNDZ.US)$$LIGAND PHARMACEUTICAL INC (LGNXZ.US)$$LIGAND PHARMACEUTICAL INC (LGNYZ.US)$$LIGAND PHARMACEUTICAL INC (LGNZZ.US)$ by 8,277 shares since Feb 28, 2024, with a total value of approximately $712.24K.

1715982557144232208.png

What is Form 144?

Form 144: Notice of Proposed Sale of Securities is a document issued by the Securities and Exchange Commission (SEC). Individuals such as executive officers and affiliates of a US-listed company must submit this form to the SEC when they intend to sell more than 5,000 shares or units of that company's stock, or if the sale price adds up to more than $50,000 in any three-month period. This regulation is known as Rule 144, under the Securities Act of 1933.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment